In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Matthew T VillaumeDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0002-0857-9542 Haley E RamseyDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0009-0007-1201-250X Valeria ImpedovoDepartment of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX.ORCID 0000-0002-2166-4303 Michael DavidsonDivision of General Internal Medicine and Public Health, Department of Medicine, Vanderbilt University School of Medicine Nashville, TN, USA.
Maria P ArrateDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0009-0005-3292-7489 Anand K SinghLaboratories of Neuroimmunology, Department of Symptom Research, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6855-3352 Yujin LeeDepartment of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX.ORCID 0009-0007-6540-4267 Yara F AlmadaniDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0009-0009-6271-4352 Sovira ChaudhryDepartment of Medical Oncology, Montefiore Einstein Cancer Center, Bronx, NY, USA.
Benjamin J ReismanDepartment of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7847-2612 Ming JiangDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0002-1927-5667 Sarah OlmsteadDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Agnieszka E GorskaDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0009-0005-2446-1527 Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN.
Peter M GraceLaboratories of Neuroimmunology, Department of Symptom Research, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8999-1220 Stefano TizianiDepartment of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX.ORCID 0000-0002-7230-0307 Michael R SavonaDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0003-3763-5504 Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MUsing social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MONCOLOGY: CHEMOTHERAPY, IMMUNOLOGY, BIOLOGYT32CA009071 · NCI · JOHNS HOPKINS UNIVERSITY · PI Mary Y Armanios, Nilofer S. Azad · 1985 to 2026
$12.8MSingle Cell Methods for Bioeffector Discovery and AnalysisR01CA226833 · NCI · VANDERBILT UNIVERSITY · PI BRIAN O BACHMANN, Jonathan Michael Irish · 2019 to 2026
$6.1MTargeting mitochondrial complex I in acute lymphoblastic leukemiaR01CA231364 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2019 to 2024
$2.9MVOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7MPQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and ChemobrainR01CA227064 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRACE, PETER M, SHEPHERD, ANDREW JOHN · 2018 to 2023
$2.2MDefining the mitochondrial metabolic regulation of systemic innate inflammationR35GM154838 · NIGMS · UNIVERSITY OF TENNESSEE KNOXVILLE · PI Andrew J Monteith · 2024 to 2026
$1.1MNCATS NIH HHS UL1 TR001427NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA226833NCI NIH HHS R01 CA227064NCI NIH HHS R01 CA231364NCI NIH HHS R21 CA318444NCI NIH HHS T32 CA009071NCI NIH HHS T32 CA217834NEI NIH HHS P30 EY008126NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS R35 GM154838
6 · The paper itselfAbstract
Targeting oxidative phosphorylation (OXPHOS) represents an attractive therapeutic strategy in acute myeloid leukemia, which exhibits exceptional dependence on mitochondrial respiration compared to normal hematopoietic cells. However, clinical attempts to exploit this vulnerability have been limited by on-target toxicity to healthy tissue. Here, we comprehensively compare the cellular consequences of inhibiting distinct nodes of the electron transport chain in AML. We demonstrate that selective inhibition of the F
Identifiers
PMID42523261
PMCPMC13404747
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390